COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,196 Articles (22,713 medRxiv, 8,483 bioRxiv)

Most recent first Previous |  Page 851: Articles 8501-8510  | Next

Understanding the role of mask-wearing during COVID-19 on the island of Ireland
Fitz-Simon, N., Ferguson, J., Alvarez, A., Sofonea, M. T., Kamiya, T.
10.1101/2022.03.25.22272946 — Posted: 2022-03-25
Impact of Vaccination, Prior Infection, and Therapy on Delta and Omicron Variants
Wang, X., Zein, J., Ji, X., Lin, D.
10.1101/2022.03.24.22272901 — Posted: 2022-03-25
Vaccine Effectiveness Against Hospitalization Among Adolescent and Pediatric SARS-CoV-2 Cases in Ontario, Canada
Simmons, A. E., Amoako, A., Grima, A., Murison, K., Tuite, A., Fisman, D.
10.1101/2022.03.24.22272919 — Posted: 2022-03-25
Booster dose of BNT162b2 in a CoronaVac primary vaccination protocol improves neutralization of SARS-CoV-2 Omicron variant
Campos, G. R. F., Almeida, N. B. F., Filgueiras, P. S., Corsini, C. A., Gomes, S. V. C., de Miranda, D. A. P., de Assis, J. V., Silva, T. B. S., Alves, P. A., Fernandes, G. R., de Oliveira, J. G., Rahal, P., Grenfell, R. F. Q., Nogueira, M. L.
10.1101/2022.03.24.22272904 — Posted: 2022-03-25
COVID-19 outcomes associated with clinical and demographic characteristics in patients hospitalized with severe and critical disease in Peshawar
Imran, M., Uddin, A., Yousaf, M., Khan, S., Khan, A. J., Iqbal, Z., Jan, R., Khan, S., Khan, M. S.
10.1101/2022.03.24.22272884 — Posted: 2022-03-25
Vaccine Adverse Event Reporting System (VAERS): Evaluation of 31 Years of Reports and Pandemics' Impact
Almadani, O., Alshammari, T. M.
10.1101/2022.03.23.22272819 — Posted: 2022-03-25
International Travel-Related Control Measures to contain The Covid-19 Pandemic: An update to a Cochrane Rapid Review
Hohlfeld, A., abdullahi, l., Abou-Setta, A. M., Engel, M. E.
10.1101/2022.03.24.22271703 — Posted: 2022-03-25
A Computational Pipeline to Identify Potential Drug Targets and Interacting Chemotypes in SARS-CoV-2
Sandholtz, S. H., Drocco, J. A., Zemla, A. T., Torres, M. W., Silva, M. S., Allen, J. E.
10.1101/2022.03.24.485222 — Posted: 2022-03-25
SARS-CoV-2 harnesses host translational shutoff and autophagy to optimize virus yields: The role of the envelope (E) protein
Waisner, H., Grieshaber, B., Saud, R., Henke, W., Stephens, E. B., Kalamvoki, M.
10.1101/2022.03.24.485734 — Posted: 2022-03-25
Autoantibody discovery across monogenic, acquired, and COVID19-associated autoimmunity with scalable PhIP-Seq
Vazquez, S. E., Mann, S. A., Bodansky, A., Kung, A. F., Quandt, Z., Ferre, E. M. N., Landegren, N., Eriksson, D., Bastard, P., Zhang, S.-Y., Liu, J., Mitchell, A., Mandel-Brehm, C., Miao, B., Sowa, G., Zorn, K., Chan, A. Y., Shimizu, C., Tremoulet, A., Lynch, K., Wilson, M. R., Kämpe, O., Dobbs, K., Delmonte, O. M., Notarangelo, L. D., Burns, J. C., Casanova, J.-L., Lionakis, M. S., Torgerson, T. R., Anderson, M. S., DeRisi, J. L.
10.1101/2022.03.23.485509 — Posted: 2022-03-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).